Results 61 to 70 of about 63,898 (235)
Thalidomide does not interact with P-glycoprotein [PDF]
, 2018 Background: There is growing clinical interest in thalidomide for the treatment of various disorders due to its anti-inflammatory, immunomodulatory, and anti-angiogenic properties. In numerous clinical trials thalidomide is used as an adjunct to standard
Drewe, Juergen +2 more
core
Thalidomide and Thrombosis [PDF]
Pathophysiology of Haemostasis and Thrombosis, 2003 Department of Hematology, San Bortolo Hospital Via Rodolfi – 36100 Vicenza (Italy) Tel. 39 0444 99 3626, Fax 39 0444 92 0708 E-Mail rodeghiero@hemato.ven.it Thalidomide is a glutamic acid derivative that exerts potent anti-angiogenic activity, modulation of T-cell activity and direct effects on tumour cells and their microenvironment.
Rodeghiero, Francesco, Elice, Francesca
openaire +3 more sources
The role of the pediatrican in the effort to prevent congenital malformations [PDF]
, 2011 N
Brent, Robert L, Dr.
core +1 more source
Making regulation responsive to commercial interests: streamlining drug industry watchdogs [PDF]
, 2002 New prescription drugs are developed and tested for quality, safety, and efficacy by the pharmaceutical industry, and little or no drug testing is conducted by governments in modern industrialised countries.
Abraham, John
core +2 more sources
Biomedicine & Pharmacotherapy, 2002 Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its activity in cancer. After its success in myeloma, it has been investigated in other plasma cell dyscrasias, myelodysplastic syndromes, gliomas, Kaposi's sarcoma, renal cell carcinoma, advanced breast cancer, and colon cancer. Thalidomide causes responses in 30-50% of
Seema Singhal, Jayesh Mehta
openaire +3 more sources
Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure [PDF]
, 2015 AIM: Portal hypertension is a common complication of liver cirrhosis and significantly increases mortality and morbidity. Previous reports have suggested that the compound thalidomide attenuates portal hypertension (PHT).
Korshunov, Vyacheslav A. +4 more
core +1 more source
Structural dynamics of the cereblon ligand binding domain.
PLoS ONE, 2015 Cereblon, a primary target of thalidomide and its derivatives, has been characterized structurally from both bacteria and animals. Especially well studied is the thalidomide binding domain, CULT, which shows an invariable structure across different ...
Marcus D Hartmann +4 more
doaj +1 more source
Cukurova Medical Journal, 2019 Limited data are available on eosinophilia as a drug adverse event with immunosuppressant and modulator. We report a case of 40 year old male patient treated with thalidomide for lepra reaction developed thalidomide induced eosinophilia.
Deeptanshu Nirmal Chandu +3 more
doaj +1 more source
Trends and predictors of women's risk perception about medications that may cause birth defects [PDF]
, 2019 The purpose of this study was to evaluate the proportion of women who reported perception of medications as a risk for birth defects, whether perceptions have changed over time, and identify socioeconomic and medical factors that are independent ...
Samuelson, Mark
core
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma [PDF]
, 2015 Immunomodulatory drugs (IMiDs) have potent anti-tumor activities in multiple myeloma (MM) and are able to enhance the cytotoxic function of natural killer (NK) cells, important effectors of the immune response against MM.
Abruzzese, MARIA PIA +12 more
core +2 more sources